Century Therapeutics Inc. has announced compelling preclinical research results for its new Type 1 diabetes program, CNTY-813. The therapy uses iPSC-derived beta islets engineered with the company's Allo-Evasion™ 5.0 technology to overcome immune rejection and provide durable glucose control without the need for chronic immunosuppression. According to Century, preclinical data show rapid and sustained normalization of glucose levels in diabetic mouse models, significant glucose-stimulated insulin secretion, and resistance to immune cell-mediated rejection. The company also reported success in producing these beta islets at scale using a suspension bioreactor process. IND-enabling studies are on track to begin by the end of 2025, with an IND submission planned as early as 2026. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.